

Table S1. Clinical characteristics of tissue samples.

Group type	Mean age (years) and range	Total serum PSA (ng/ml) at diagnosis	Type of specimens*	No of cases	No of cases with PCa and type of cancer	Cancer features***	No of cases with HGPIN
Untreated	60 (44-72)	< 4.0	RP**	25	25 (clinical)	pT2a,10 cases with GS 6 (3+3), 10 cases with GS 8 (4+4), PZ	20
Hormonally treated	62 (43-73)	< 4.0	RP**	19	19 (clinical)	pT2a, GS 6 (3+3)****, PZ	18
Hormone-independent	73 62-80)	< 4.0	TURP	9	9 (clinical)	See footnote#	0

*RP: radical prostatectomy; TURP: transurethral resection of the prostate

** The reason for prostate biopsy was an abnormal DRE and TRUS in most of the cases or PSA velocity in a few cases (data not shown)

***Pathologic stage according to the 2009 TNM revision (all the patients were N0 and there was no evidence of metastasis related to prostate neoplasia); GS: Gleason score; PZ: cancer origin in the peripheral zone; NA: not applicable

****GS as determined in the initial prostate biopsy. All the cases showed a good to excellent degree of regression following androgen ablation

#This is not a homogeneous group in terms of cancer features at the time of initial presentation. Cancer was locally advanced in all cases and was detected because of an elevated PSA and abnormal DRE and/or TRUS. Cancer was documented bioptically and the Gleason score was equal to or greater than 6. All the patients were under complete androgen blockade for an extended period. TURP was performed when urinary obstructive symptoms appeared because the cancer had become hormone-independent. Morphologically the cancer present in the TURP specimens had the features of a high grade tumor showing no effect of androgen blockade.

Table S2. Characterization of c-FLIP expression in prostate tissue

	Untreated (3+3)	Untreated (4+4)	Treated	Castrate-Resistant
Type of tissue	Mean	Mean	Mean	Mean
Normal prostate	89.6 ± 10.43* (76-102)	90.8 ± 10.69 (73-101)	74.6 ± 21.7 (30-95)	/
HGPIN	185.2 ± 8.07 (174-196)	184.8 ± 9.63 (168-192)	136.7 ± 31.75 (82-185)	/
Prostate cancer	193.2 ± 4.09 (188-199)	202 ± 14.85 (192-228)	128.6 ± 23.36 (100-172)	282.9 ± 12.13 (269-300)

Mean ± standard deviation and range (in parenthesis).